Key facts
- It has raised $2.8M; the latest was Early Stage VC ($2.8M) in Apr 2025.
- Notable investors include Investissement Quebec.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Synucure Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Synucure Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synucure Therapeutics
Operator of a biotechnology company intended to conduct research in brain degenerative disorders. The company's drug may be able to prevent and/or reverse several features associated with parkinson's disease, enabling patients to get a cure and aid in better parkinson's diagnosis.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2021
- Employees
- 4
- Website
- synucure.com/fr/accueil
- Ownership
- Privately Held (backing)
Synucure Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synucure Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synucure Therapeutics in its N-PORT filings yet. We sweep new filings monthly.